GlassScriptPhysician profile
Hayden Mk Boyce
NPI 1164631818
$8,092.80
in general payments reported to CMS, 2019-2025
21 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $1,756 · 2021: $337 · 2022: $2,664 · 2023: $442 · 2024: $1,153 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Travel and Lodging: $403 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,589.39 |
| Travel and Lodging | $403.24 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,201.14 | 2022-2025 | Mazor X System, Stealth Autoguide System, Percept PC Brainsense |
| Medtronic USA, INC. | $1,720.08 | 2019-2020 | |
| Abbott Laboratories | $1,236.45 | 2019-2025 | Proclaim, Infinity, Absolute Pro |
| Depuy Synthes Sales INC. | $812.16 | 2019-2025 | Fibergraft Bg Morsels, Arch, Trialtis |
| Stryker Corporation | $255.28 | 2023-2024 | Everest Spinal System, Adherus Autospray Dural Sealant, Universal Neuro 3 |
| Boston Scientific Corporation | $179.45 | 2024-2025 | General - Dbs, Vercise |
| Intrinsic Therapeutics | $168.93 | 2024 | Barricaid Acd (Annular Closure Device) |
| Lemaitre Vascular, INC. | $125.00 | 2023 | Anastoclip Gc 8cm (Medium) |
| Insightec,INC | $80.43 | 2025 | Exablate |
| Neurelis, INC. | $58.60 | 2024-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $38.00 | 2024-2025 | Motpoly Xr |
| Jazz Pharmaceuticals INC. | $34.61 | 2025 | |
| Pfizer INC. | $23.87 | 2024 | |
| Ucb, INC. | $23.19 | 2024 | Fintepla |
| Clearpoint Neuro, INC. | $21.53 | 2024 | Clearpoint |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $21.20 | 2022 | |
| Csl Behring | $20.00 | 2024 | Kcentra |
| Ipsen Biopharmaceuticals, INC | $19.06 | 2024 | Dysport |
| Otter Pharmaceuticals, LLC | $18.36 | 2025 | Sympazan |
| Acadia Pharmaceuticals INC | $17.78 | 2025 | Nuplazid |
| Brainlab, INC. | $17.68 | 2023 | Image Guided Surgical Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayden Boyce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.